Until now, the antiviral effect of leflunomide has not been evaluated in clinical trials in patients with viral infections, but its suppressive effect on IL-17 production has already been tested in patients with rheumatoid arthritis [152]. This evidence concerns the gene IL17A and rheumatoid arthritis.